| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2025-06-25 |
| タイトル |
|
|
タイトル |
Extended single-dose toxicity study of [At]meta-astatobenzylguanidine in normal mice in preparation for the first-in-human clinical trial of targeted alpha therapy for pheochromocytoma and paraganglioma. |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Taiki Joho
Songji Zhao
Ken-Ichi Nishijima
Naoyuki Ukon
Saki Shimoyama
Atsushi Yamashita
Komei Washino
Tatsuya Higashi
Masao Kobayakawa
Tohru Shiga
Kazuhiro Takahashi
Hiroshi Ito
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Targeted alpha-particle therapy (TAT) is promising with a greater therapeutic effect than conventional beta radionuclide therapy. To develop human clinical trials of [At]meta-astatobenzylguanidine ([At]MABG), we have conducted an extended single-dose toxicity study of [At]MABG in normal mice in consultation with the Pharmaceuticals and Medical Devices Agency (PMDA). We are currently working for human clinical trials of [At]MABG. After consultation with the Pharmaceuticals and Medical Devices Agency, we conducted a single-dose toxicity study of [At]MABG in normal mice in preparation for a human clinical trial of [At]MABG. |
| 書誌情報 |
Annals of nuclear medicine
発行日 2025-06
|
| 出版者 |
|
|
出版者 |
Springer Japan |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1864-6433 |
| PubMed番号 |
|
|
|
識別子タイプ |
PMID |
|
|
関連識別子 |
40531424 |
| DOI |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1007/s12149-025-02065-0 |
